Stay updated with breaking news from Pascal Deschatelets. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Get Rating) have been given a consensus recommendation of “Moderate Buy” by the fifteen brokerages that are covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, three have issued a hold recommendation, seven have assigned a buy recommendation and one has issued […]
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Get Rating) shares hit a new 52-week high during mid-day trading on Wednesday . The stock traded as high as $80.77 and last traded at $80.03, with a volume of 124231 shares. The stock had previously closed at $79.65. Wall Street Analyst Weigh In APLS has been the topic of […]
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Get Rating) insider Pascal Deschatelets sold 12,000 shares of the stock in a transaction on Monday, April 10th. The shares were sold at an average price of $78.21, for a total transaction of $938,520.00. Following the sale, the insider now directly owns 1,027,313 shares of the company’s stock, valued at […]
Dupont Capital Management Corp boosted its position in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Get Rating) by 139.2% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 15,177 shares of the company’s stock after acquiring an additional 8,833 shares during the […]
NJ State Employees Deferred Compensation Plan acquired a new position in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Get Rating) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 6,000 shares of the company’s stock, valued at approximately $310,000. Several other hedge funds have also […]